Traws Pharma, Inc. 0T2.F Stock
Traws Pharma, Inc. Price Chart
Traws Pharma, Inc. 0T2.F Financial and Trading Overview
| Traws Pharma, Inc. stock price | 0.47 EUR |
| Previous Close | 1.05 EUR |
| Open | 1.09 EUR |
| Bid | 1.09 EUR x N/A |
| Ask | 1.13 EUR x N/A |
| Day's Range | 1.09 - 1.09 EUR |
| 52 Week Range | 0.59 - 1.39 EUR |
| Volume | 2K EUR |
| Avg. Volume | 196 EUR |
| Market Cap | 24.09M EUR |
| Beta (5Y Monthly) | 1.784507 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20 EUR |
0T2.F Valuation Measures
| Enterprise Value | -12831050 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.8384616 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 106.60875 |
| Price/Book (mrq) | 0.99908346 |
| Enterprise Value/Revenue | -56.775 |
| Enterprise Value/EBITDA | 0.594 |
Trading Information
Traws Pharma, Inc. Stock Price History
| Beta (5Y Monthly) | 1.784507 |
| 52-Week Change | -7.22% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.39 EUR |
| 52 Week Low | 0.59 EUR |
| 50-Day Moving Average | 0.93 EUR |
| 200-Day Moving Average | 0.85 EUR |
0T2.F Share Statistics
| Avg. Volume (3 month) | 196 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 20.97M |
| Float | 20.83M |
| Short Ratio | N/A |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 7.40% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -9571.68% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.26% |
| Return on Equity (ttm) | -63.27% |
Income Statement
| Revenue (ttm) | 226K EUR |
| Revenue Per Share (ttm) | 0.01 EUR |
| Quarterly Revenue Growth (yoy) | 0% |
| Gross Profit (ttm) | 226K EUR |
| EBITDA | -21618000 EUR |
| Net Income Avi to Common (ttm) | -20617000 EUR |
| Diluted EPS (ttm) | -0.88 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.22M EUR |
| Total Cash Per Share (mrq) | 1.63 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.799 |
| Book Value Per Share (mrq) | 1.091 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16541000 EUR |
| Levered Free Cash Flow (ttm) | -9227000 EUR |
Profile of Traws Pharma, Inc.
| Country | Germany |
| State | PA |
| City | Newtown |
| Address | 12 Penns Trail |
| ZIP | 18940 |
| Phone | 267 759 3680 |
| Website | https://www.onconova.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 16 |
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Q&A For Traws Pharma, Inc. Stock
What is a current 0T2.F stock price?
Traws Pharma, Inc. 0T2.F stock price today per share is 0.47 EUR.
How to purchase Traws Pharma, Inc. stock?
You can buy 0T2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Traws Pharma, Inc.?
The stock symbol or ticker of Traws Pharma, Inc. is 0T2.F.
Which industry does the Traws Pharma, Inc. company belong to?
The Traws Pharma, Inc. industry is Biotechnology.
How many shares does Traws Pharma, Inc. have in circulation?
The max supply of Traws Pharma, Inc. shares is 25.3M.
What is Traws Pharma, Inc. Price to Earnings Ratio (PE Ratio)?
Traws Pharma, Inc. PE Ratio is now.
What was Traws Pharma, Inc. earnings per share over the trailing 12 months (TTM)?
Traws Pharma, Inc. EPS is -0.8 EUR over the trailing 12 months.
Which sector does the Traws Pharma, Inc. company belong to?
The Traws Pharma, Inc. sector is Healthcare.